MBGP.F Stock Overview

A pharmaceutical company, develops and commercializes medical products primarily in Sweden. More details

MBGP.F fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 87% below our estimate of its fair value

Revenue is forecast to grow 105.03% per year

Risk Analysis

Makes less than USD$1m in revenue (SEK9M)

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap ($452M)

Volatile share price over the past 3 months compared to the US market

My Notes

Capture your thoughts, links and company narrative

Moberg Pharma AB (publ) Competitors

Sol-Gel Technologies

NasdaqCM:SLGL

US$25.0m

VYNE Therapeutics

NasdaqCM:VYNE

US$40.9m

Incannex Healthcare

NasdaqGM:IXHL

US$33.5m

Cara Therapeutics

NasdaqCM:CARA

US$21.0m

Price History & Performance

Summary of share price highs, lows and changes for Moberg Pharma
Historical stock prices
Current Share Price	SEK 0.87
52 Week High	SEK 4.30
52 Week Low	SEK 0.78
Beta	0.93
1 Month Change	-4.93%
3 Month Change	-17.53%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-86.18%

Recent updates

Shareholder Returns

	MBGP.F	US Pharmaceuticals	US Market
7D	6.8%	-0.07%	2.4%
1Y	n/a	1.5%	25.0%

Return vs Industry: Insufficient data to determine how MBGP.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how MBGP.F performed against the US Market.

Price Volatility

Is MBGP.F's price volatile compared to industry and market?
MBGP.F volatility
MBGP.F Average Weekly Movement	17.0%
Pharmaceuticals Industry Average Movement	10.8%
Market Average Movement	6.5%
10% most volatile stocks in US Market	18.7%
10% least volatile stocks in US Market	3.3%

Stable Share Price: MBGP.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: MBGP.F's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2006	9	Anna Ljung	www.mobergpharma.se

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013.

Moberg Pharma AB (publ) Fundamentals Summary

How do Moberg Pharma's earnings and revenue compare to its market cap?
MBGP.F fundamental statistics
Market cap	US$41.03m
Earnings (TTM)	-US$1.66m
Revenue (TTM)	US$798.27k

52.9x

P/S Ratio

-25.5x

P/E Ratio

Is MBGP.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MBGP.F income statement (TTM)
Revenue	SEK 8.78m
Cost of Revenue	SEK 2.33m
Gross Profit	SEK 6.45m
Other Expenses	SEK 24.70m
Earnings	-SEK 18.25m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 11, 2025

Earnings per share (EPS)	-0.39
Gross Margin	73.46%
Net Profit Margin	-207.75%
Debt/Equity Ratio	0%

How did MBGP.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/22 15:16
End of Day Share Price	2025/01/22 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Moberg Pharma AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Bjorn Rydell	ABG Sundal Collier Sponsored
Klas Pyk	Nordea Markets
Mats Hyttinge	Redeye